quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·189d
PRRelease
Kezar Life Sciences Inc. logo

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

KZR· Kezar Life Sciences Inc.
Health Care
Original source

Companies

  • KZR
    Kezar Life Sciences Inc.
    Health Care

Recent analyst ratings

  • Oct 17UpdateJefferies$7.00
  • Oct 17UpdateWilliam Blair-
  • Aug 11UpdateWells Fargo$4.00
  • Mar 16UpdateWilliam Blair-
  • Dec 8UpdateWells Fargo$19.00
  • Nov 16UpdateHC Wainwright & Co.$20.00

Related

  • SEC10d
    SEC Form SC 14D9 filed by Kezar Life Sciences Inc.
  • SEC11d
    SEC Form SC TO-T filed by Kezar Life Sciences Inc.
  • SEC17d
    SEC Form SCHEDULE 13G filed by Kezar Life Sciences Inc.
  • SEC20d
    SEC Form SC14D9C filed by Kezar Life Sciences Inc.
  • SEC20d
    Kezar Life Sciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
  • SEC22d
    Amendment: SEC Form SCHEDULE 13D/A filed by Kezar Life Sciences Inc.
  • SEC24d
    SEC Form SC14D9C filed by Kezar Life Sciences Inc.
  • SEC24d
    Kezar Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022